Compare SWBI & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SWBI | ENGN |
|---|---|---|
| Founded | 1852 | 1999 |
| Country | United States | Canada |
| Employees | N/A | 82 |
| Industry | Ordnance And Accessories | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 691.4M | 647.1M |
| IPO Year | 2000 | N/A |
| Metric | SWBI | ENGN |
|---|---|---|
| Price | $14.56 | $1.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $14.00 | ★ $21.08 |
| AVG Volume (30 Days) | 405.2K | ★ 2.1M |
| Earning Date | 06-17-2026 | 06-11-2026 |
| Dividend Yield | ★ 3.37% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $474,661,000.00 | N/A |
| Revenue This Year | $7.61 | N/A |
| Revenue Next Year | $3.72 | N/A |
| P/E Ratio | $291.20 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.73 | $1.49 |
| 52 Week High | $15.79 | $12.25 |
| Indicator | SWBI | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 44.96 | 22.55 |
| Support Level | $13.80 | N/A |
| Resistance Level | $15.24 | $8.32 |
| Average True Range (ATR) | 0.41 | 0.57 |
| MACD | -0.12 | -0.58 |
| Stochastic Oscillator | 18.00 | 0.07 |
Smith & Wesson Brands Inc is a U.S.-based leader in firearm manufacturing. It operates under one reportable segment: Firearms, which includes firearms distribution and manufacturing services. The company manufactures handguns, long guns, sporting rifles, shooting gear, and suppressor products. The firm's brand portfolio consists of Smith and Wesson, M&P, Thompson/Center Arms, Performance Center, and Gemtech; which are used for defense, law enforcement, hunting, and sporting purposes. The company operates internationally, with the majority of income generated by the U.S. market from its handgun products.
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.